AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

AZN.UK

10,328

+1.65%↑

INDV

835

+1.46%↑

Search

GlaxoSmithKline PLC

Închisă

SectorSănătate

1,398 2.61

Rezumat

Modificarea prețului

24h

Curent

Minim

1363

Maxim

1403

Indicatori cheie

By Trading Economics

Venit

1.3B

1.8B

Vânzări

-601M

7.5B

P/E

Medie Sector

18.415

56.602

EPS

44.9

Randament dividend

4.65

Marjă de profit

23.576

Angajați

68,629

EBITDA

2B

3.1B

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+3.9% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.65%

2.45%

Următoarele câștiguri

30 iul. 2025

Data viitoare de dividende

10 iul. 2025

Următoarea dată ex-dividende

14 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-174M

57B

Deschiderea anterioară

1395.39

Închiderea anterioară

1398

Sentimentul știrilor

By Acuity

46%

54%

150 / 382 Clasament în Healthcare

GlaxoSmithKline PLC Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

14 mai 2025, 11:01 UTC

Achiziții, Fuziuni, Preluări

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - Update

14 mai 2025, 06:39 UTC

Achiziții, Fuziuni, Preluări

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion

12 mai 2025, 09:36 UTC

Principalele dinamici ale pieței

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30 apr. 2025, 07:03 UTC

Câștiguri

GSK Sales, Profit Rise on Boost from HIV, Cancer Drugs -- Update

30 apr. 2025, 06:37 UTC

Câștiguri

GSK Sales, Profit Rise on Boost from Cancer Drugs

15 mai 2025, 15:20 UTC

Top știri

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

14 mai 2025, 06:08 UTC

Achiziții, Fuziuni, Preluări

GSK PLC to Buy Efimosfermin from Boston Pharmaceuticals

14 mai 2025, 06:03 UTC

Achiziții, Fuziuni, Preluări

GSK PLC: Deal Includes Potential Success-Based Milestone Payments of $800M

14 mai 2025, 06:03 UTC

Achiziții, Fuziuni, Preluări

GSK PLC to Pay $1.2B Upfront

14 mai 2025, 06:03 UTC

Achiziții, Fuziuni, Preluări

GSK to Buy Efimosfermin for up to $2B

14 mai 2025, 06:00 UTC

Achiziții, Fuziuni, Preluări

GSK to Buy Efimosfermin

12 mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12 mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

30 apr. 2025, 08:54 UTC

Market Talk
Câștiguri

GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk

30 apr. 2025, 07:49 UTC

Market Talk
Câștiguri

GSK's Specialty Meds Sustain Growth, Blenrep Comeback Remains Key -- Market Talk

30 apr. 2025, 07:06 UTC

Market Talk
Câștiguri

GSK Outperforms Expectations Despite RSV Vaccine Setback -- Market Talk

30 apr. 2025, 06:03 UTC

Câștiguri

GSK: Confident in Long-Term Outlook

30 apr. 2025, 06:03 UTC

Câștiguri

GSK Declares Dividend of 16p Vs 15p

30 apr. 2025, 06:02 UTC

Câștiguri

GSK 1Q Core EPS 44.9p

30 apr. 2025, 06:02 UTC

Câștiguri

GSK 1Q Core Operating Profit GBP2.53B

30 apr. 2025, 06:02 UTC

Câștiguri

GSK 1Q Net Pft GBP1.62B

30 apr. 2025, 06:01 UTC

Câștiguri

GSK Backs 2025 View

30 apr. 2025, 06:00 UTC

Câștiguri

Analysts Saw GSK PLC 1Q Net Profit at GBP1.67B

30 apr. 2025, 06:00 UTC

Câștiguri

Analysts Saw GSK PLC 1Q Turnover at GBP7.42B

30 apr. 2025, 06:00 UTC

Câștiguri

GSK PLC 1Q EPS 39.3p

30 apr. 2025, 06:00 UTC

Câștiguri

GSK PLC 1Q Adj EPS 44.9p

30 apr. 2025, 06:00 UTC

Câștiguri

GSK PLC 1Q Pre-items, Pretax Pft GBP2.43B

30 apr. 2025, 06:00 UTC

Câștiguri

GSK PLC 1Q Oper Pft GBP2.22B

30 apr. 2025, 06:00 UTC

Câștiguri

GSK PLC 1Q Net Pft GBP1.62B

30 apr. 2025, 06:00 UTC

Câștiguri

GSK PLC 1Q Pretax Pft GBP2.11B

Comparație

Modificare preț

GlaxoSmithKline PLC Așteptări

Obiectiv de preț

By TipRanks

3.9% sus

Prognoză pe 12 luni

Medie 1,415.66 GBX  3.9%

Maxim 2,290 GBX

Minim 13.55 GBX

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruGlaxoSmithKline PLC - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

14 ratings

3

Cumpărare

7

Păstrare

4

Vânzare

Sentiment

By Acuity

150 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.